89Zr-olaratumab Dosimetry in Participants With Soft Tissue Sarcoma
NCT06537596
·
clinicaltrials.gov ↗
PHASE1
Phase
RECRUITING
Status
50
Enrollment
INDUSTRY
Sponsor class
Conditions
Soft Tissue Sarcoma
Interventions
DRUG:
89Zr-DFOsq-olaratumab (89Zr-TLX300-CDx)
Sponsor
Telix Pharmaceuticals (Innovations) Pty Ltd